Depends as it looks to me Ceo is a Smart Man, broke away as the company and debt holders are not getting most of the company, but most investors don't realize that. The dilution needs to controlled as  so barring a major turnaround like you stated FDA, I see the stock eventually drifting back into the single digits. Or for having identified the risk as being to great for the potential reward. Id rather here more however, upon investigation, you can see that 1) the company fundamentals do improve, justifying a pop in the stock and 2) if it does start to pull up, as risky as it can be, we will make some money. A deal to exchange ownership has been pending and taking place which is why BMSN is more like an option than a stock. If they figure out how to unlock the value of their on-demand licenses, the stock is worth several times its current price.